FDA Publishes Photos in Warning Letter to Indian Drug Manufacturer – A First for Transparency

On January 15, 2025, the FDA published a warning letter to Granules India Limited that included 16 photographs documenting specific cGMP violations observed during an unannounced inspection. This marks the first time the agency has embedded visual evidence directly within a warning letter, departing from its standard practice of issuing text-only citations.

Regulatory Context

FDA warning letters are issued under the agency's authority under the Federal Food, Drug, and Cosmetic Act (FD&C Act) when inspections reveal significant violations of cGMP requirements codified in 21 CFR Parts 210 and 211. These letters serve as official notice that a facility is out of compliance and may face enforcement actions including import alerts, consent decrees, or facility deregistration if violations are not corrected.

Historically, warning letters have described violations in text form, sometimes referencing photographs "on file" with the agency but not releasing them publicly. FDA Form 483 observations—issued at the conclusion of inspections—similarly describe deficiencies without visual documentation. The inclusion of photographs in the Granules India warning letter represents a significant shift in the agency's transparency posture.

The warning letter cites violations of 21 CFR 211.42 (design and construction of facilities), 21 CFR 211.56 (sanitation), 21 CFR 211.67 (equipment cleaning and maintenance), and 21 CFR 211.84 (testing and approval of components). The accompanying photographs show peeling paint near production equipment, rust on machinery surfaces, gaps in facility walls exposing insulation, and inadequate separation between manufacturing areas.

Key Details

The inspection took place at Granules India's Gagillapur facility from September 18-26, 2024. The facility manufactures active pharmaceutical ingredients (APIs) distributed to finished dosage form manufacturers in the United States and other markets. The FDA classified the inspection as Official Action Indicated (OAI), the most serious outcome category.

The 16 photographs published with the warning letter include:

• Rust on process equipment used in API manufacturing
• Peeling paint and exposed surfaces in production areas
• Structural gaps in walls and ceilings near sterile manufacturing zones
• Discolored residue on equipment surfaces
• Inadequate segregation between raw material storage and production

Each photograph is captioned with the specific cGMP violation it documents. The FDA letter states that "photographic evidence is included to provide clarity on the nature and severity of the observed conditions."

The agency gave Granules India 15 working days from receipt to respond with a corrective action plan addressing each cited deficiency. The letter warns that failure to correct violations promptly may result in regulatory actions including refusal of product entry at U.S. borders and possible criminal prosecution.

Impact on Wholesale Distributors and Supply Chain Partners

Wholesale drug distributors source APIs and finished products from international manufacturers who may now face heightened inspection scrutiny and documentation standards. The inclusion of photographs raises the evidentiary bar for FDA enforcement and signals that visual documentation of violations will become part of the public compliance record.

For distributors conducting supplier qualification audits, this development has three operational implications:

1. Supplier risk assessment must now account for visual inspection findings. Text-based 483 observations may understate the severity of facility conditions. Distributors should request photographic documentation during supplier audits or engage third-party auditors equipped to capture visual evidence.

1. Import alert risk increases for entities sourcing from cited facilities. The FDA may place Granules India or specific products on Import Alert 66-40 (Detention Without Physical Examination of Drugs), requiring private lab testing and certification before entry. Distributors with Granules-sourced products in their supply chain should verify current import status via the FDA's Import Alert database.

1. DSCSA trading partner verification includes manufacturing facility compliance. Under 21 USC 360eee-1(c)(4), authorized trading partners must be "licensed, registered, or authorized" to conduct business. A warning letter documenting facility-level violations may affect an entity's registration status or trigger additional due diligence requirements under distributor quality agreements.

Distributors should monitor FDA's Enforcement Report and Warning Letters database weekly for updates to suppliers' compliance status. Entities with quality agreements covering API sourcing should review whether photographic documentation standards are specified in audit protocols.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs, of which 1,234 hold active FDA registration. While Granules India is an API manufacturer (not tracked in the directory as it does not operate as a U.S. wholesale distributor), the warning letter carries implications for the distributors that source from facilities with similar compliance profiles.

Of the 73 entities in the directory with FDA recalls or enforcement actions on record, 41 involve foreign-sourced products where manufacturing deficiencies were cited as contributing factors. The average compliance score for entities with at least one recall is 38/100, compared to the directory average of 51/100. This 13-point gap reflects the cumulative impact of enforcement signals on an entity's compliance posture.

The distribution of compliance scores across the directory shows that 919 entities (72%) fall into the "Fair" tier (26-75 points). These entities typically hold state licenses and FDA registration but may lack NABP accreditation or have limited publicly available quality system documentation. For distributors in this tier sourcing APIs or finished products from international manufacturers, the FDA's new photographic documentation standard raises the stakes for supplier qualification audits.

Practical Guidance for QA and Procurement Teams

Distributors should take the following steps in response to the FDA's increased transparency on facility conditions:

• Cross-reference supplier FDA registration status in ColdChainCheck's directory at /directory. Entities without active registration may face heightened inspection risk if they begin importing products from facilities under FDA scrutiny.

• Review quality agreements with API suppliers to confirm audit documentation standards. If agreements require "compliance with cGMP," specify whether photographic evidence of facility conditions is required during site audits. The Granules India warning letter demonstrates that text descriptions may not capture the severity of violations.

• Monitor Import Alert 66-40 weekly for additions. Distributors sourcing from facilities placed on detention without physical examination must provide private lab certification before products can enter U.S. commerce. This creates supply chain delays and increases landed cost.

• Document supplier qualification decisions with reference to FDA warning letters. If a distributor chooses to continue sourcing from a facility under FDA enforcement, the quality agreement should specify corrective action timelines and re-audit schedules. Auditors reviewing trading partner verification under DSCSA will expect this documentation.

ColdChainCheck tracks FDA enforcement actions as part of the compliance score methodology. Warning letters reduce an entity's score in the "Regulatory History" category (up to 10-point deduction). For detailed guidance on interpreting FDA enforcement signals, see the Compliance Guides section.

Disclaimer: This article is informational only and does not constitute legal or regulatory advice. Entities should consult qualified legal counsel and verify all compliance requirements with the relevant regulatory authority.